… monoclonal antibody targeted to BRAF V600E is now commercially … BRAF-mutant tumors
will be highlighted, and the prognostic and predictive implications of a BRAF V600E mutation …

… ) is a potent inhibitor of mutated BRAF. It has marked antitumor effects against melanoma
cell lines with the BRAF V600E mutation but not against cells with wild-type BRAF. A phase 1 …

BRAF (V600E) mutation is the most frequent genetic alteration in papillary thyroid carcinomas
(PTCs) that are 80–90% of all thyroid cancers. We evaluated the relationship between …

… and tumor regression in xenografts presenting BRAF-V600E mutant cells. The first clinical
… as expression of the therapeutic target (BRAF V600E-mutant protein) has been shown to be …

… In microsatellite-stable tumors, this mutation was related to poor … V600E mutation was
present or absent (76.2% and 75.0%, respectively). We conclude that the BRAF V600E mutation in …

… mutation carriers when compared with controls. Most importantly, we report on a patient with
confirmed BRAF V600E mutation … doses of the mutation-specific BRAF inhibitor vermurafenib…

… BRAF are now showing great promise as a novel therapeutic strategy for melanomas harboring
activating BRAF V600E mutations … on the role of mutated BRAF in the development and …

… patients negative for both the BRAF V600E mutation and the indicated clinicopathological
factor. … Kaplan-Meier Survival Curves of the Interaction of BRAF V600E Mutation With Age in …

… monoclonal BRAF V600E mutation-specific antibody that can differentiate BRAF V600E and
… Here we describe the development of a BRAF V600E mutation-specific antibody that can be …

… In this open-label, phase 3 trial, we enrolled 665 patients with BRAF V600E–mutated metastatic
colorectal cancer who had had disease progression after one or two previous regimens. …